The production of generic drugs in India: Would be affected by new trade agreement with EU

Love, James
April 2011
BMJ: British Medical Journal (International Edition);4/2/2011, Vol. 342 Issue 7800, p721
Academic Journal
The author reflects on the trade agreement negotiated between European Union (EU) and India which may affect the production of generic drugs. The author says that the deal, which restricts ownership and enforcement of intellectual property for medical inventions, if implemented, may shrink the global market for affordable generic drugs. He adds that India is among the few developing countries that have enough market for the suppliers of such drugs, which mainly account the treatment of AIDS.


Related Articles

  • Patently pending. James, David // BRW;9/5/2002, Vol. 24 Issue 35, p64 

    Discusses the threat posed to intellectual property rights of developing countries by global corporations. Percentage of intellectual property rights held by the developed world; Problems in establishing an intellectual property regime; Need for effective intellectual property initiatives.

  • Foreign actors and intellectual property protection regulations in developing countries. Brandl, Kristin; Darendeli, Izzet; Mudambi, Ram // Journal of International Business Studies;Jul2019, Vol. 50 Issue 5, p826 

    International agreements and institutions affect innovation in developing countries. We analyze the impact of advanced country multinational enterprises (AMNEs) and supranational organizations on the regulatory adoption of global intellectual property protection standards. In particular, we...

  • Compulsory Licenses: The Authors Reply. Beall, Reed F.; Attaran, Amir; Kuhn, Randall // Health Affairs;Jun2015, Vol. 34 Issue 6, p1068 

    A response by Reed F. Beall and Amir Attaran to a letter to the editor about their article on the use of compulsory licenses to access minimally priced drugs worldwide in the March 2015 issue is presented.

  • After years of peaks, 'patent cliff' to slow generics growth. DeArment, Alaric // Drug Store News;11/17/2008, Vol. 30 Issue 14, p46 

    The article reports on the impact of the decline of the supply of expiring patents on the generic drug companies in the U.S. It is said that generic drug companies will have to adapt as market becomes increasing commoditized. According to IMS vice president of industry relations Doug Long,...

  • News in brief….  // PharmacoEconomics & Outcomes News;12/3/2005, Issue 492, p11 

    The article presents information on a study conducted in The Netherlands which examined the effect of drug patent expiry for enalapril on the sale of generic drugs. The researchers found that after the patent expiry, the sale of generic drugs in the country increased.

  • The Ethics of Intellectual Property Rights in an Era of Globalization. Shah, Aakash Kaushik; Warsh, Jonathan; Kesselheim, Aaron S. // Journal of Law, Medicine & Ethics;Winter2013, Vol. 41 Issue 4, p841 

    Since the 1980s, developed countries, led by the United States and the countries of the European Union, have sought to incorporate intellectual property rights provisions into global trade agreements. These countries successfully negotiated the World Trade Organization's 1994 Agreement on...

  • Basic Survival Needs and Access to Medicines - Coming to Grips with TRIPS: Conversion + Calculation. Van Puymbroeck, Rudolf V. // Journal of Law, Medicine & Ethics;Fall2010, Vol. 38 Issue 3, p520 

    'Access to medicines' is a broad concept. After a review of three authoritative frameworks that help to identify its constitutive components, this essay summarizes the actual situation on the ground in low- and middle-income countries on the basis of recent empirical work. An analysis of survey...

  • The quest for generic biotechnology pharmaceuticals in the USA. Kowalski, Thomas J.; Fekete, Pamela; Yvon, Anne-Marie C. // Journal of Commercial Biotechnology;Apr2005, Vol. 11 Issue 3, p271 

    As patent protection expires on the first generation of biotechnology products, such as human growth hormone and erythropoietin, there is an impetus for the development and marketing of generic equivalents. Currently there is no statutory or regulatory framework governing generic biotechnology...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics